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Abstract
Diffuse large B cell lymphoma (DLBCL) is a clinically and genetically heterogeneous disease. A small subset of DLBCLs has
translocationsinvolvingtheMYClocusandanadditionalgrouphasamolecularsignatureresemblingBurkittlymphoma(mBL).
Presently, identification of such cases by morphology is unreliable and relies on cytogenetic or complex molecular methods
such as gene transcriptional profiling. Herein, we describe an immunohistochemical (IHC) method for identifying DLBCLs with
increased MYC protein expression. We tested 77 cases of DLBCL and identified 15 cases with high MYC protein expression
(nuclear staining in .50% of tumor cells). All MYC translocation positive cases had increased MYC protein expression by this
IHC assay. In addition, gene set enrichment analysis (GSEA) of the DLBCL transcriptional profiles revealed that tumors with
increased MYC protein expression (regardless of underlying MYC translocation status) had coordinate upregulation of MYC
target genes, providing molecular confirmation of the IHC results. We then generated a molecular classifier derived from the
MYC IHC results in our cases and employed it to successfully classify mBLs from two previously reported independent case
series, providing additional confirmation that the MYC IHC results identify clinically important subsets of DLBCLs. Lastly, we
foundthatDLBCLswithhighMYCproteinexpressionhadinferioroverall survivalwhentreatedwithR-CHOP.Inconclusion,the
IHC method described herein can be used to readily identify the biologically and clinically distinct cases of MYC-driven DLBCL,
which represent a clinically significant subset of DLBCL cases due to their inferior overall survival.
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Introduction
The transcription factor and cell cycle regulator MYC (c-MYC)
is a well-recognized oncoprotein in B-cell lymphoma. Nearly all
Burkitt lymphomas (BLs) exhibit elevated MYC protein expression
due to transcriptional deregulation following a balanced translo-
cation involving MYC and, most commonly, the immunoglobulin
heavy chain locus (IgH) [1]. In contrast, only 10% of diffuse large
B-cell lymphomas (DLBCLs) harbor a MYC translocation [2–4].
However, additional DLBCLs that may not harbor a MYC
translocation exhibit features of ‘‘molecular Burkitt lymphoma
(mBL)’’ by gene expression profiling (GEP) [3,5]. Although
patients with DLBCL are typically treated with rituximab-
containing CHOP-like chemotherapy regimens, the therapy for
BL includes alternating combinations of more intensive multi-
agent chemotherapy [6–8]. It is now recognized that the presence
of a MYC rearrangement is an independent predictor of poor
outcome in DLBCL patients who are treated with standard,
DLBCL-directed therapy [2–4,9]. Thus, the sub-classification of
DLBCL based on MYC status has become critical for selecting
patients who are candidates for more intensive, BL-type regimens.
Presently, routine identification of cases of DLBCL with MYC
abnormalities is not possible by morphology and, therefore, is
dependent upon cytogenetic or complex molecular methods
[3,5,10]. Herein, we report a standardized immunohistochemical
(IHC) approach to assess MYC protein expression in formalin-
fixed paraffin-embedded tissue (FFPE) which readily identifies
DLBCLs with high nuclear MYC protein expression. Biologically,
primary DLBCL cases with increased MYC protein expression
exhibit coordinate upregulation of MYC target genes and have a
poorer outcome following R-CHOP treatment. In addition, a
molecular classifier derived from the gene transcriptional profiles
of the MYC-driven DLBCLs identified by the immunohistochem-
ical assay largely captures tumors classified as mBLs in previously
reported series [3,5].
Methods
Case selection
56 primary (de novo) DLBCLs from 2004–2009 with matched
frozen and FFPE tissue as well as 21 secondary (recurrent or
transformed) DLBCLs with FFPE tissue were identified through
the Department of Pathology, Brigham and Women’s Hospital
and reviewed to confirm presence of diagnostic tissue and final
diagnosis [11]. Clinical history, treatment and survival data were
obtained from chart reviews with IRB approval. Cases for survival
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33813analysis had documentation of an R-CHOP based treatment
regimen.
Immunohistochemical Analysis
4 mm thick FFPE full tissue sections were stained for MYC
(rabbit monoclonal anti-human MYC antibody; catalog #1472-1,
Epitomics, Inc., Burlingame, CA, USA) [12] in the Specialized
Histopathology Laboratory and the Anatomic Pathology Immu-
nohistochemistry Laboratory (Department of Pathology, Brigham
and Women’s Hospital) on Ventana Benchmark XTs (Ventana
Medical Systems, Tucson, AZ, USA) using extended antigen
retrieval (CC1 buffer), anti-MYC antibody (final concentration
0.56 mg/ml) and signal amplification (mouse anti-rabbit reagent
followed by rabbit anti-mouse reagent, Figure 1). The percentage
of positive tumor nuclei was manually scored from 0 to 100% in
10% intervals and was also assessed with an Aperio ScanScope
(Aperio Technologies Inc., Vista, CA), ImageScope software, and
an optimized algorithm for nuclear staining (Nuclear V.9, Aperio,
Inc.) [13]. Independent scoring by two hematopathologists showed
very high concordance for final MYC classification (kappa
statistic=0.941). The scoring results from the pathologist (MJK)
are represented in Figure 2. The Ki67 score was taken from the
diagnostic pathology reports for the majority of cases. For those
cases in which Ki67 was not performed at the time of diagnosis,
the stain was performed as part of this study and interpreted by a
pathologist (SJR) blinded to the genetics of the tumor.
Genetic Analysis
MYC translocations were characterized according to standard
and published protocols of karyotypic analysis and by fluorescent
in situ hybridization (FISH) with a Vysis LSI MYC dual color,
break apart rearrangement probe (catalog # 05J91-001, Abbott
Molecular, Abbott Park, IL, USA) [14].
Bioinformatic Analysis
Gene expression profiling of primary DLBCLs and GSEA
analysis for MYC and 20 MYC target genes [5] were performed
according to standard protocols as described (See Supplementary
Methods S1) [14–16]. A molecular classifier derived from
differential gene expression between the MYC IHC-High and
MYC IHC-Low DLBCLs was generated according to previously
published protocols [14](See Supplementary Methods S1).
Results
IHC analysis of 56 primary DLBCL cases revealed a spectrum
of total tumor cell nuclei (ranging from 10% to 90%) that stained
positive for MYC by manual scoring (Figures 1 & 2A). Digital
image analysis (Aperio ScanScope) revealed concordant findings
with manual scoring (Figure S1). Cases in which the majority
(.50%) of tumor nuclei stained positive for MYC (10 cases,
Figures 1 & 2A) exhibited moderate to strong staining intensity,
while cases in which #50% of tumor nuclei were MYC positive
had dim to moderate staining intensity (46 cases, Figures 1 & 2A).
All of the cases of primary DLBCL with a MYC rearrangement
(9%; a frequency consistent with prior reports) [2] showed MYC
staining in .50% of tumor nuclei (range of 60–90%, manual
scoring) (Figure 2A). An additional 4 cases of primary DLBCL
without a MYC translocation had increased MYC expression by
IHC (Figure 2A). Likewise, when we assessed MYC staining in an
independent cohort of 21 cases of secondary DLBCL, we found
that all MYC translocation positive cases had .50% MYC positive
tumor nuclei and that an additional two cases of secondary
DLBCL without a MYC translocation also had increased MYC
expression (Figure 2B).
A subset of cases (n=24) was re-stained an additional two times
over a span of six months, once on the same staining instrument
and once on a separate staining instrument in a distinct laboratory.
Quantification of MYC positive tumor nuclei for each case by two
independent pathologists revealed that the staining and the
quantification procedure were highly reproducible (Figures S2;
S3). A comparison of the MYC IHC scores with the Ki67
proliferation scores for the DLBCLs revealed only a weak
correlation (Spearman r=0.33, p=0.003, Figure 3); indicating
that the biomarkers are not redundant.
Figure 1. Immunohistochemical detection of MYC in representative Primary DLBCLs. Photomicrographs of select tumors and reactive
tissue stained for MYC (positive staining=brown nuclei). Positive control (Burkitt lymphoma with a confirmed MYC translocation) revealed uniform,
intense staining in .90% of tumor cells (Burkitt). In contrast, reactive lymphoid tissue revealed variable staining in only 10% of normal lymphocyte
nuclei (Tonsil). Representative images from DLBCL cases and associated percent MYC+ tumor nuclei: Case 1, 90% MYC+; Case 7, 70% MYC+; and Cases
35 and 38, 30% MYC+. MYC staining was exclusively nuclear in all cases under the described staining conditions.
doi:10.1371/journal.pone.0033813.g001
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analysis (i.e., those with .50% MYC-positive nuclei vs. those with
#50% MYC-positive nuclei). This cut-point identified all cases
with an underlying MYC translocation, in two independent
cohorts. Tumors that scored as MYC IHC-High (.50% MYC-
positive nuclei) showed a spectrum of immunophenotypic and
morphological features (Figure 4, Table 1). Upon additional
review, no cases matched criteria for BL and only 2 of 15 cases had
some morphologic characteristics that might suggest as ‘‘B-cell
lymphoma, unclassifiable, with features intermediate between
DLBCL and BL’’ (Int. DLBCL/BL) by the 2008 WHO criteria
(Figure 4D; Table 1). Although the 2 cases showed intermediate to
large sized tumor cells with fine nuclear chromatin, the cases
lacked a ‘‘starry sky’’ appearance at low magnification, the tumor
nuclei showed marked pleomorphism, and the tumors exhibited
immunophenotypes that are not consistent with BL (i.e., BCL2+)
or Int. DLBCL/BL (i.e. Ki67,90%) and, therefore, are best
classified as DLBCL, NOS.
Gene set enrichment analysis (GSEA) revealed that primary
DLBCL cases with .50% MYC-positive tumor nuclei exhibited
coordinate upregulation of MYC and MYC target genes [5] when
compared to cases with #50% positive tumor nuclei (Figure 5A).
Importantly, similar results were obtained when the GSEA was
restricted to MYC-translocation negative cases with .50% MYC-
positive tumor nuclei by IHC (Figure 5B), providing molecular
confirmation that the increased MYC protein expression detected
in these cases correlates with the upregulation of MYC and MYC
target genes.
Two independent laboratories have reported that a subset of
DLBCLs have a gene transcriptional profile resembling Burkitt
lymphoma (‘‘molecular Burkitt lymphoma’’, mBL), and that these
cases largely, but not completely, overlap with those tumors
Figure 2. Comparison of MYC protein expression and MYC translocation status in cases of Primary (de novo) DLBCL; (A). Comparison
of percent MYC positive tumor nuclei for Burkitt lymphoma, reactive tonsil and 56 primary DLBCLs with their corresponding MYC translocation status
(bar graph; pink=MYC translocation, green=no MYC translocation, gray=not determined). Tumors with an IHC score of .50% are indicated in red at
left. Tumors are arranged by IHC-determined percentage of MYC-positive nuclei. Comparison of MYC protein expression and MYC
translocation in cases of Secondary DLBCL; (B). Comparison of percent MYC positive tumor nuclei for Burkitt lymphoma, reactive tonsil and 21
cases of recurrent or transformed DLBCLs with their corresponding MYC translocation status (bar graph; pink=MYC translocation, green=no MYC
translocation). Tumors with an IHC score of .50% are indicated in red at left. Tumors are arranged by IHC-determined percentage of MYC-positive
nuclei.
doi:10.1371/journal.pone.0033813.g002
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whether DLBCLs with high levels of staining for MYC resemble
those previously categorized as mBL by transcriptional profiling.
Although we did not have access to the previously categorized
tumor samples to directly test them by IHC, we developed an
ensemble molecular classifier of MYC-driven DLBCL using the
transcriptional profiles from a subset of our DLBCLs categorized
as MYC IHC-High (i.e., .60% tumor cells positive) and MYC
IHC-Low (i.e., ,50% tumor cells positive) and applied this
ensemble classifier to the previously published transcriptional
profile datasets (Supplementary Methods S1). Our MYC IHC-
derived molecular classifier correctly identified the vast majority of
Figure 3. Comparison of MYC IHC score and Ki67 proliferation
index for all cases analyzed. Cases with a MYC-translocation are
colored in red and cases without a MYC-translocation are colored in
black. The two biomarkers demonstrate a weak but positive correlation
(Spearman r=0.33, p=0.003).
doi:10.1371/journal.pone.0033813.g003
Figure 4. Morphological features of select MYC IHC-High
DLBCLs. Hematoxylin and Eosin stained sections (all 10006 original
magnification) of (A) Relapse case #2, DLBCL NOS; (B). Relapse case #4,
DLBCL NOS; (C) Primary case #1, DLBCL, immunoblastic variant; (D)
Primary case #3, DLBCL, NOS, with some morphological features that
might suggest B-cell lymphoma, unclassifiable, with features interme-
diate between DLBCL and BL (see text for details).
doi:10.1371/journal.pone.0033813.g004
Table 1. Pathological Features of MYC IHC-High DLBCL.
Case
Number MYC IHC (%) MYC Trans-location? IHC- Positive IHC- Negative Ki67 (%) Morphological Diagnosis
16 DLBCL 26 DLBCL
1 90 Yes CD20, CD10, BCL6,
BCL2
50 DLBCL-Immunoblastic
2 80 Yes CD20, BCL6, BCL2 CD10 65 DLBCL-Immunoblastic
3 80 Yes CD20, CD10, BCL6,
BCL2
60 DLBCL, NOS
4 70 Yes CD20, BCL6, BCL2 CD10 80 DLBCL, NOS
5 70 No CD20, BCL2 CD10, BCL6 90 DLBCL-Immunoblastic
6 70 No CD20, CD10, BCL6,
BCL2
95 DLBCL, NOS
7 70 No CD20, BCL6 BCL2, CD10 85 DLBCL, NOS
8 60 No CD20, CD10, BCL6,
BCL2
95 DLBCL, Anaplastic
9 60 Yes CD20, BCL2 CD10 90 DLBCL, NOS
10 60 N/A CD20, BCL6, BCL2 CD10 N/A DLBCL, NOS
1 90 Yes CD20, CD10, BCL2 CD5 55 DLBCL, NOS
2 80 No CD20 CD10 90 DLBCL, NOS
3 70 Yes CD20, CD10, BCL6,
BCL2
75 DLBCL, NOS
4 70 No CD20, CD10, BCL2 60 DLBCL, NOS
5 70 Yes CD20, BCL6, BCL2 CD10 95 DLBCL, NOS
doi:10.1371/journal.pone.0033813.t001
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cases, 89%) (Table 2, Tables S1 and S2) [3,5]; thereby providing
molecular evidence that MYC IHC can identify tumors with a
transcriptional profile resembling mBL.
Lastly, in order to shed light on the clinical significance of
DLBCL with high MYC protein detected by IHC, we compared
the overall survival of patients with primary DLBCL whose tumors
exceeded our threshold for MYC expression (.50%) with those
below the threshold (#50%). Among patients who were confirmed
to have received R-CHOP-based therapy and had available long-
term follow-up, those patients whose tumors had .50% MYC
positivity had poorer overall survival compared to those with
#50% (Figure 6). Three of the six tumors in the group exhibiting
.50% MYC positivity harbored a MYC translocation and three
did not. None of the tumors in the group with ,50% MYC
positivity harbored a MYC translocation (Table 3). Tumors in the
cohort came from patients with a range of international prognostic
index scores (IPI), however cases classified as MYC IHC-High
were associated with a higher IPI than cases classified as MYC
IHC-Low (p=0.06, Kruskal-Wallis test, Table 3). The size of the
patient cohort is not sufficient to determine whether high MYC
expression is a poor prognostic marker independent of IPI (DSN,
Department of Biostatistics, DFCI).
Discussion
Diffuse large B cell lymphoma represents a clinically and
genetically heterogeneous group of tumors. Various morphologic,
immunohistochemical, cytogenetic and molecular subgroups have
been identified [11]. One such important subgroup includes cases
with a MYC translocation that occurs in approximately 10% of all
cases and is associated with a poor prognosis [2]. Another
clinically significant subgroup harbor a molecular signature
resembling Burkitt lymphoma, and these cases are often referred
to as molecular Burkitt lymphoma (mBL). In some reports, this
subgroup has also been associated a poor prognosis [3,5].
Currently, cases of DLBCL with a MYC translocation or mBL
signature cannot be readily identified by morphologic or
immunohistochemical features. [10]
Herein, we have described a standardized immunohistochem-
ical method for detecting MYC protein expression that can readily
identify cases of DLBCL with a MYC translocation. More
specifically, we have found that cases of both primary and
secondary DLBCL with a MYC translocation reproducibly have
.50% of tumor nuclei which are strongly positive for MYC
protein. Gene Set Enrichment Analysis (GSEA) of the primary
DLBCLs with .50% MYC positive tumor nuclei correlates with
upregulated MYC and MYC target genes, providing confirmation
that the detection of a high MYC protein expression by IHC is
associated with an activated MYC transcriptional profile.
A novel observation from this study is the broad range of MYC
protein expression in DLBCL. We observed MYC IHC scores
Figure 5. GSEA of MYC target genes in tumors characterized
for MYC protein expression; (A). Gene Set Enrichment Analysis
(GSEA) of all primary DLBCL cases reveals coordinate upregulation of
MYC and MYC target genes (black vertical lines) in tumors with .50%
MYC positive tumor nuclei (including MYC translocation-positive and –
negative cases) (See Supplementary Methods S1 for additional details).
Gene Set Enrichment Analysis (GSEA) of MYC-target genes in
MYC translocation–negative Primary DLBCL tumors; (B) MYC
translocation-negative primary DLBCL cases with .50% MYC positive
tumor nuclei have coordinate upregulation of MYC and MYC target
genes (black vertical lines).
doi:10.1371/journal.pone.0033813.g005
Table 2. Correlation of MYC IHC Gene Transcriptional Profile Classifier Result with mBL Signature.
MYC IHC-High/Low Transcriptional Profile Dave
1 DLBCL Signature Hummel
2 DLBCL Signature
mBL Non-mBL mBL Non-mBL
High 82 9 7
Low 0 64 2 109
p-value
3 ,0.0001 ,0.0001
1)Series includes 74 cases of large B-cell lymphoma identified as having a Burkitt signature (mBL) or not (non-mBL) based on transcriptional profiles.
2)Series includes 127 cases of diffuse large B-cell lymphoma identified as having mBL or non-mBL based on transcriptional profiles. The MYC IHC High/Low gene
expression classifier results for the cases that were identified as ‘‘Intermediate’’ by Hummel are included in Table S2.
3)Fisher’s exact test.
doi:10.1371/journal.pone.0033813.t002
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tumors as MYC IHC-High versus MYC IHC-Low was desirable.
We established a cut-off value for classifying tumors as the lowest
MYC IHC score that captures all cases with a confirmed MYC
translocation (.50% tumor nuclei positive for MYC). This
decision was further justified by data indicating that this cut-point
identified a group of patients with inferior clinical outcome when
treated with R-CHOP (Figure 6). We also observe a statistically
significant difference in clinical outcome when we raise the cut-
point for classifying tumors as MYC IHC-High to .60% positive
tumor nuclei (p=0.001, Log-rank test). However when lower cut-
points are used (i.e. MYC IHC .40%), we do not observe a
statistically significant difference in outcome (DSN, Dept.
Biostatistics, DFCI). It should be noted that our cohort of patients
with outcome data is small (38 patients), and that these results will
need to be validated in additional patient cohorts and across
multiple institutions.
Unexpectedly, we found that the Ki67 proliferation index of the
tumors showed only a weak correlation with the MYC IHC score
(Spearman r=0.33, p=0.003, Figure 3, Table 1). This result
suggests that Ki67 is not a good surrogate biomarker for MYC
IHC, and that a high Ki67 proliferation index and a MYC-
translocation are not as closely associated in DLBCL as they are in
BL. This result is in agreement with some prior reports showing
that Ki67 proliferation index is not a good predictor of MYC-
translocation status in DLBCL. [9][17]
An additional novel finding from this study is the identification
of DLBCLs with high MYC protein in the absence of a MYC-
translocation. Gene set enrichment analysis (GSEA) confirmed
increased MYC transcriptional activity in MYC IHC-High
DLBCLs lacking a MYC-translocation (Figure 5B), and thus, there
must be alternative mechanisms for MYC deregulation. We found
that one primary MYC IHC-High DLBCL case (Case #8) had
copy number gain in MYC (6 copies), however the remaining cases
had only 2 copies of MYC. Alternative cellular alterations resulting
in increased MYC expression have been described for tumors
other than DLBCL, and these include transcriptional and post-
transcriptional deregulation [18,19]. Determining the mechanisms
that are responsible for MYC deregulation in MYC IHC-High
DLBCLs lacking a MYC-translocation will be a focus of future
efforts.
There has been much interest in tumors conforming to the
pathological diagnosis of DLBCL but harboring a gene transcrip-
tional profile resembling BL (‘‘molecular Burkitt lymphoma’’,
mBL). A subset of mBL cases lacks a MYC-translocation and is not
identified by routine pathologic or cytogenetic techniques. We did
not have access to the primary tissue samples from the original
case series describing mBL to test directly by IHC. However, we
used the transcriptional profiles from a subset of our cases to derive
an ensemble molecular classifier that we applied to the published
transcriptional profiles of DLBCLs analyzed by Dave et al., and
Hummel et al. It is important to note that in constructing our
ensemble classifier, we used the transcriptional profiles from our
set of DLBCLs with unequivocally high (.60%) and low (,50%)
levels of MYC staining. Our classifier correctly identified the
majority of DLBCLs previously classified as ‘‘mBL’’ (17/19 cases,
89%), and correctly identified the majority of DLBCLs previously
classified as ‘‘Non-mBL’’ (173/182 cases, 95%). The results are
highly significant (p,0.0001, Table 2), and indicate that MYC
IHC can identify a set of tumors with transcriptional profiles
resembling those previously categorized as mBL.
Figure 6. Outcome analysis according to MYC protein expres-
sion in Primary (de novo) DLBCL. Kaplan-Meier curve depicting the
statistically significant (p=0.01, log rank test) difference in the overall
survival for the 38 primary DLBCL patients treated with R-CHOP. Tumors
were grouped by MYC IHC score .50% (n=6) or #50% (n=32).
doi:10.1371/journal.pone.0033813.g006
Table 3. Characteristics of R-CHOP treated Patient Cohort used for Survival Analysis.
Category Subcategory MYC High
1,2 MYC Low
1
Number of Patients 63 2
Gender – Female:Male 4:2 11:21
Median Age [years] (range) 66 (50–73) 59 (27–81)
MYC Translocations 30
IPI Low 20/1 1 15
Low/Intermediate 221 4
High/Intermediate 231 4
High 24/5 3 4
NA 0 5
Median Follow Up [months] (range) 31 (2–69) 55 (6–87)
1)MYC High cases show positive staining for MYC in .50% of tumor nuclei; MYC Low cases show positive staining for MYC in #50% tumor nuclei.
2)Cases classified as MYC IHC-High are associated with a higher IPI than cases classified as MYC IHC-Low (p=0.06, Kruskal-Wallis test).
doi:10.1371/journal.pone.0033813.t003
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previously categorized as ‘‘mBL’’ or ‘‘Non-mBL’’ (Table 2). Two
cases categorized as mBL in the Hummel series but categorized as
‘‘MYC IHC-Low Gene Transcriptional Profile’’ by our classifier
were negative for a MYC translocation. Of the 7 cases classified as
‘‘Non-mBL’’ cases by the Hummel classification but classified as
‘‘MYC IHC-High Gene Transcriptional Profile’’ by our classifier,
2 cases had a MYC-translocation. Furthermore, one of the two
previously reported series of cases (Hummel et al.) also included an
‘‘Intermediate mBL/non-mBL’’ category of DLBCL. When we
applied our classifier to this category of tumors (Table S2), a subset
of cases (10/38, 26%) sorted as having a ‘‘MYC IHC-High gene
transcriptional profile’’, and a subset of cases (28/38, 74%) sorted
as having a ‘‘MYC IHC-Low gene transcriptional profile’’. Direct
staining of the primary tissues from these case series will be
necessary to determine the true sensitivity and specificity of MYC
IHC in identifying DLBCLs with a profile of mBL and to establish
whether MYC IHC is robust enough to capture DLBCLs that
classify as ‘‘Intermediate mBL/non-mBL’’.
The WHO Classification of Tumours of Haematopoietic and
Lymphoid Tissues (4th edition) includes the diagnostic category
‘‘B-cell lymphoma, unclassifiable, with features intermediate
between diffuse large B-cell lymphoma and Burkitt lymphoma’’
(Int. DLBCL/BL) to encompass a heterogeneous group of
tumors that do not meet the specific criteria of DLBCL or BL.
[11] As defined, this category includes cases that morphologically
resemble BL but exhibit atypical immunophenotypic or genetic
profile, and cases with morphologic features overlapping BL
and DBLCL but exhibit a phenotypic or genetic profile
compatible with BL. At this time, this category does not include
cases of morphologically typical DLBCL and have a MYC-
rearrangement.
Each of the 77 cases examined in this study were originally
diagnosed as ‘‘Diffuse large B-cell lymphoma, NOS’’ by the WHO
Classification scheme. Re-examination of hematoxylin and eosin
stained sections from our 15 cases scored as MYC IHC-High
revealed a spectrum of morphological patterns consistent with
typical DLBCL, NOS, for most cases. However we also observed
cases with features consistent with the immunoblastic and
anaplastic variants of DLBCL (Table 1, Figure 4). Only two cases
showed intermediate to large cell size and fine nuclear chromatin
that could raise the possibility of classifying the tumors as ‘‘B-cell
lymphoma, unclassifiable, with features intermediate between
DLBCL and BL’’ by the 2008 WHO criteria. However these cases
lacked a ‘‘starry sky’’ appearance at low magnification, showed
marked nuclear pleomorphism at high magnification (Figure 4D),
did not demonstrate a high Ki67 proliferation index (60% and
75%, respectively) and had an abnormal immunophenotype
(BCL2+) and, therefore we felt that that the classification as
DLBCL, NOS, was appropriate. Overall, we did not find a
unifying set of morphological or phenotypic features that would
allow pathologists to identify cases of DLBCL with high MYC
activity with certainty.
Despite the morphologic appearance of DLBCL, NOS, we find
that patients with MYC IHC-High DLBCL do poorly when
treated with R-CHOP. This result is consistent with results from
others who have reported that patients with DLBCLs harboring a
MYC-rearrangement exhibit inferior clinical outcome compared to
those without a MYC-rearrangement when treated with standard
chemotherapy. [2,3,9] Therefore, we believe that the WHO
diagnostic category of Int. DLBCL/BL as currently defined may
not fully capture cases of MYC-driven DLBCL. A more clinically
relevant diagnostic category within the WHO might be ‘‘MYC-
driven diffuse large B-cell lymphoma’’. Adoption of such a
category will require further discussion among expert pathologists
and a careful retrospective analysis of the literature.
IHC is utilized for diagnostic purposes by a large proportion of
pathology laboratories in the United States on a daily basis.
However the technique and interpretation of the results are
recognized as difficult to standardize. [20] One of the goals of this
study is to provide a reproducible method for detecting and
quantifying MYC staining in FFPE biopsy samples that can serve
as a template for other pathology laboratories that may wish to
implement the test.
To ensure precision in the automated staining protocol, we
stained identical samples of tonsil, Burkitt lymphoma, and 22
DLBCL cases including the primary DLBCL case #9 (DLBCL
with MYC-translocation near the cut-point for MYC IHC-High)
three times. For two staining runs, the same staining instrument
was used. For the third staining run, a separate staining instrument
(also a Ventana Benchmark XT) located in a separate laboratory
was employed. Microscopic examination of the slides revealed that
the staining was reproducible, even when the staining runs were
spaced months apart (Figure S2). Moreover, the final classification
of each DLBCL tested did not change across staining runs. To
establish the precision in quantifying the stained tumor samples, all
cases were scored independently by two hematopathologists and
by computer based image analysis algorithm (Figures S1; S3). We
found very high inter-observer agreement between pathologists
(kappa statistic=0.941) and between the pathologists and the image
analysis algorithm for the final tumor classification. Thus our data
suggest that the results of this assay can be reproducible over time.
In implementing MYC IHC in any new laboratory, we suggest
strict fidelity to the validated staining protocol described here and
through the consistent inclusion of appropriate positive and
negative control tissues whenever the assay is performed.
Specifically, one should use the specific antibody clone (Y69,
Epitomics Inc.) validated in this manuscript since other antibodies
may perform differently. The antibody should be used at the final
concentration stated (0.56 microg/mL) using the standard
immunohistochemical staining platform and detection kit (Ven-
tana Benchmark XT) as per our validation protocol for formalin
fixed paraffin embedded tissues. Since the antibody concentration
as supplied by the company varies from lot to lot it is important to
use the same final concentration of antibody rather than the same
dilution or titer. The provider of the antibody (Epitomics, Inc.)
maintains the antibody concentration data for each lot and
provides it upon request. Other automated staining platforms (i.e.
Leica Bond, DAKO autostainer) are also likely to be amenable for
detecting MYC in FFPE tissues, however the optimal final
concentration of anti-MYC antibody may differ on these staining
platforms and separate validations will need to be performed. [12]
Furthermore, we strongly suggest that positive and negative
control tissues should be included in each staining run. These
calibrators ensure the general technical success of the assay and
serve as a guide for interpreting the stained samples of interest. For
each staining run we always include reactive tonsil and Burkitt
lymphoma with a confirmed MYC translocation to ensure that the
antibody and staining platform performs as expected. We would
further suggest, as a control tissue, inclusion of a known DLBCL
with a MYC translocation at or near the cut-point for classification
as MYC IHC-High. This will help establish the threshold for
classification as MYC IHC-High across staining runs- especially
when prospectively testing cases. In establishing the precision of
our assay over multiple staining runs, we included the primary
DLBCL case #9 (a DLBCL with MYC-translocation and 60% of
the tumor nuclei positive for MYC staining, Figure 2A) as a
control. Despite the consistency of MYC staining in our hands, we
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threshold control cases, preferably the exact same cases to ensure
the consistency of the results over time and recommend others do
so as well. As with any new IHC procedure implemented within a
CLIA-approved laboratory, each institution will need to complete
an initial internal validation on a set of genetically defined
DLBCLs (i.e. assessed for a MYC translocation by FISH) to
determine the exact testing conditions required for their
institution’s tissue fixation and processing protocols.
We are implementing MYC IHC into our daily practice of
diagnostic surgical pathology but, at least initially, as part of a
prospective study to validate the findings from the current
retrospective analysis. Our diagnostic pathology department, like
a large proportion of pathology departments in the United States,
is equipped with automated immunostainers. IHC is performed
daily and on all cases of lymphoma. Therefore, implementation of
MYC IHC is straightforward in our daily practice. MYC IHC will
be included in the standard panel of immunohistochemical stains
performed on each case of suspected DLBCL and the MYC IHC
score determined manually by a diagnostic surgical pathologist. All
cases of DLBCL will also undergo FISH analysis to assess for a
MYC-translocation.
If a prospective analysis confirms the reliability of the test in
general and the cut-point for positive staining tumor nuclei
described here (.50% tumor nuclei positive for MYC), MYC
IHC will be implemented as a screening test for deciding which
cases of DLBCL we will further analyze by FISH in daily practice.
With increasing use and familiarity with MYC IHC, it is our hope
to reliably and prospectively identify patients with DLBCL and
high MYC protein who may benefit from more aggressive
chemotherapy, irrespective of their MYC-translocation status.
It is worth noting that although we used an image analysis
algorithm to independently confirm the number of positive
staining tumor nuclei obtained by manual quantification, we will
use manual quantification in daily practice. Although computer-
assisted image analysis is conceptually appealing as a means to
quantify MYC staining in daily practice, in the current form the
technique suffers limitations that are likely to limit general use.
Specifically, computer-based analyses are unable to distinguish
nuclei of tumor cells from those of admixed, reactive lymphocytes,
endothelial cells, and other non-neoplastic cells. As a result, the
algorithms can under-call the number of positive-staining tumor
nuclei (Figure S1). This problem is especially relevant to tumors
such as T-cell rich/histiocyte rich DLBCL. Moreover, despite the
increasing use of slide scanners, there is no standard diagnostic
pathology test which currently uses image analysis in lieu of manual
quantification by an expert pathologist, even when the quantifi-
cation is clinically important (i.e. enumerating CD34+ cells on
bone marrow biopsies as a marker of blasts). Thus, manual
quantification will remain our primary means to enumerate
positive-staining tumor nuclei.
In conclusion, we describe a robust and broadly applicable IHC
method for identification of increased MYC protein in FFPE from
cases of DLBCL. We show that cases of primary DLBCL with
.50% MYC-positive tumor nuclei have increased MYC activity
as assessed by GSEA and have an inferior overall survival
following R-CHOP treatment. Importantly, we show that this
IHC test has the advantage of identifying DLBCLs with
deregulated MYC expression which lack a MYC translocation
and that a molecular classifier derived from the gene expression
profile of our cases can capture tumors defined as mBL by other
groups. Although these findings will require confirmation in
additional, independent tumor cohorts, our results indicate the
feasibility and utility of IHC staining for MYC that can be
implemented as part of the standard diagnostic evaluation of
DLBCL.
Supporting Information
Figure S1 Comparison of manual and automated
analysis of MYC expression by IHC in primary DLBCL
cases; (A). Comparison of MYC IHC percent positive tumor
nuclei for each primary DLBCL determined manually by a
pathologist (grey bars) or by an image analysis algorithm using
Aperio ImageScope software (black bars). The threshold for
.50% and #50% staining is indicated (horizontal line). The
shaded area separates cases with .50% positive tumor nuclei from
cases with #50% positive tumor nuclei. Comparison of
manual and automated analysis of MYC expression by
IHC in secondary DLBCL cases; (B). Comparison of MYC
IHC percent positive tumor nuclei for each secondary DLBCL
determined manually by a pathologist (grey bars) or by an image
analysis algorithm using Aperio ImageScope software (black bars).
The threshold for .50% and #50% staining is indicated
(horizontal line). The shaded area separates cases with .50%
positive tumor nuclei from cases with #50% positive tumor nuclei.
(TIF)
Figure S2 Reproducibility of MYC IHC staining on an
automated platform. Representative images of the indicated,
identical sets of cases stained 6 months apart. All photomicro-
graphs are 10006original magnification.
(TIF)
Figure S3 Reproducibility of MYC IHC quantification.
Comparison of the average MYC IHC percent positive tumor
nuclei for each indicated case of DLBCL stained three times (twice
on one automated staining machine; once on a separate
automated staining machine in a distinct laboratory) and
determined manually by two pathologists (grey and black bars,
respectively). The standard deviation from the mean for the 3 tests
is indicated.
(TIF)
Table S1 Sub-classification of the Dave et al., DLBCL
series by pathology review, global transcriptional pro-
file, and the MYC IHC-High/Low transcriptional profile
classifier.
(XLSX)
Table S2 Sub-classification of the Hummel et al.,
DLBCL series by pathology review, global transcrip-
tional profile, and the MYC IHC-High/Low transcrip-
tional profile classifier.
(XLS)
Methods S1 Supporting information.
(DOC)
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